Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Week In Review: Innocare Strikes $937 Million Deal With Biogen For BTK Inhibitor

By: TalkMarkets
Beijing InnoCare out-licensed ex-China rights for its BTK inhibitor to Biogen​​ in a $937.5 million deal. Biogen will pay $125 million upfront and up to $812.5 million in milestones, plus royalties.
Related Stocks:
Biogen Idec
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback